The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial
Open accessAbstract
Background Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety of statin treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term efficacy and safety of lowering LDL cholesterol with statins, and here we report cause-specific mortality and major morbidity in the in-trial and post-trial periods.Methods 20,536 patients at high risk of vascular and non-vascular outcomes were allocated either 40 mg simvastatin daily or placebo, using minimised randomisation. Mean in-trial follow-up was 5·3 years (SD 1·2), and post-trial follow-up of surviving patients yielded a mean total duration of 11·0 years (SD 0·6). The primary outcome of the long-term follow-up of HPS was first post-randomisation major vascular event, and analysis was by intention to treat. This trial is registered with ISRCTN, number 48489393.Findings During the in-trial period, allocation to simvastatin yielded an average reduction in LDL cholesterol of 1·0 mmol/L and a proportional decrease in major vascular events of 23% (95% CI 19-28; p<0·0001), with significant divergence each year after the first. During the post-trial period (when statin use and lipid concentrations were similar in both groups), no further significant reductions were noted in either major vascular events (risk ratio [RR] 0·95 [0·89-1·02]) or vascular mortality (0·98 [0·90-1·07]). During the combined in-trial and post-trial periods, no significant differences were recorded in cancer incidence at all sites (0·98 [0·92-1·05]) or any particular site, or in mortality attributed to cancer (1·01 [0·92-1·11]) or to non-vascular causes (0·96 [0·89-1·03]).Interpretation More prolonged LDL-lowering statin treatment produces larger absolute reductions in vascular events. Moreover, even after study treatment stopped in HPS, benefits persisted for at least 5 years without any evidence of emerging hazards. These findings provide further support for the prompt initiation and long-term continuation of statin treatment.Funding UK Medical Research Council, British Heart Foundation, Merck & Co, Roche Vitamins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a timeframe during which a clinical benefit of lipid-lowering therapy would not be expected to emerge 10”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Heart Protection Study and Cholesterol Treatment Trialists’ Collaborators meta-analyses have demonstrated that statins provide consistent cardiovascular benefits and all-cause mortality reduction for patients [6, 7].”
In the citing paper
“Beneficial effects are retained over longterm follow-up.427”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [427]
In the citing paper
“However, in managing dyslipidemia expressed by hypertriglyceridemia, the non-HDL-C level is more useful than the LDL-C level. This has been reported in a number of studies177–179, 623, 624, 626, 627, 647).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [627]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D. R., Blackburn, H., HIGGINS, M. W., REED, D. M., Iso, H., McMillan, G. C., Neaton, J. D., Nelson, J., Potter, J., & Rifkind, B. M. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.1996.03530250059028 · Cited by 378
Should there be a moratorium on the use of cholesterol lowering drugs?
Smith, G. D., & Pekkanen, J. (1992) · British medical journal · doi:10.1136/bmj.304.6824.431 · Cited by 357
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 346
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Cited by
Sorted by citations
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Metadata
- Authors
- Heart Protection Study Collaborative Group
- Corresponding author
- Heart Protection Study Collaborative Group
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 378
- Issue
- 9808
- Pages
- 2013-2020
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3242163
- OpenAlex
- W2133184701
- Cited by
- 373
- References
- 17
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 14 · 2019: 20 · 2018: 25 · 2017: 17 · 2016: 28 · 2015: 29 · 2014: 27 · 2013: 41 · 2012: 38
- FWCI
- 38.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statin therapy, simvastatin, LDL cholesterol lowering, long-term efficacy, vascular death, major vascular events, cancer incidence, post-trial follow-up, Heart Protection Study, high-risk patients, statin safety, lipid-lowering therapy, secondary prevention of cardiovascular disease, long-term follow-up, cardiovascular risk reduction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cholesterol, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Myocardial Revascularization, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
